quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·9d
PRRelease
Ligand Pharmaceuticals Incorporated logo
Travere Therapeutics Inc. logo

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS

LGND· Ligand Pharmaceuticals IncorporatedTVTX· Travere Therapeutics Inc.
Health Care
Original source

Companies

  • LGND
    Ligand Pharmaceuticals Incorporated
    Health Care
  • TVTX
    Travere Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 14TVTXUpdatePiper Sandler$49.00
  • Mar 11LGNDUpdateBofA Securities$244.00
  • Dec 9LGNDUpdateCitigroup$270.00
  • Oct 31TVTXUpdateCitigroup$48.00
  • Jun 11TVTXUpdateH.C. Wainwright$30.00
  • Jun 11TVTXUpdateCitigroup$32.00

Related

  • INSIDER10h
    Chief Research Officer Rote William E. sold $355,719 worth of shares (9,100 units at $39.09) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 113,987 units (SEC Form 4)
  • PR1d
    Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
  • SEC2d
    SEC Form DEFA14A filed by Ligand Pharmaceuticals Incorporated
  • SEC2d
    SEC Form DEF 14A filed by Ligand Pharmaceuticals Incorporated
  • INSIDER7d
    SEC Form 4 filed by Baynes Roy D.
  • INSIDER7d
    SEC Form 4 filed by Lyons Gary A
  • INSIDER7d
    SEC Form 4 filed by Calvin Sandra
  • INSIDER8d
    SEC Form 4 filed by Heerma Peter
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022